A Study to Test an Oral Medicine, Belumosudil, in Combination With Corticosteroids in Participants at Least 12 Years of Age With Newly Diagnosed Chronic Graft Versus Host Disease.
- Conditions
- Chronic Graft Versus Host Disease
- Interventions
- Registration Number
- NCT06143891
- Lead Sponsor
- Sanofi
- Brief Summary
This is a parallel, Phase 3, two-arm study for the treatment of newly diagnosed moderate or severe chronic GVHD.
The study duration for a participant includes up to 4 weeks for screening; a treatment period until clinically meaningful cGVHD progression (defined as progression requiring addition of new systemic treatment for cGVHD), relapse/recurrence of the underlying disease, participant starts new systemic treatment for cGVHD or experiences an unacceptable toxicity, at the request of the participants or the investigators, or until the end of study is reached, whichever comes first; at least 30 days follow-up of adverse events (AEs) after the last dose until resolution or stabilization, if applicable; and long-term follow-up until death or study close-out, whichever comes first.
- Detailed Description
Up to 5 years
Recruitment & Eligibility
- Status
- RECRUITING
- Sex
- All
- Target Recruitment
- 260
- Patients must be at least 12 years of age inclusive, at the time of signing the informed consent
- Participants who have undergone allogenic HCT with newly diagnosed moderate to severe cGVHD according to NIH consensus diagnosis and staging criteria (2014)
- Participants who require systemic treatment with corticosteroids for cGVHD
- Participants who have not received any prior systemic treatment for cGVHD (including ECP)
- If participants are receiving other immunosuppressive agents for the prophylaxis or treatment of acute GVHD, the dose should be under the threshold pre-defined in protocol
- For adult participants, the body weight should be ≥40 kg. For adolescent participants, the body weight should be ≥30 kg
- Contraceptive use by men and women should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies.
- Participants or their legally authorized representative must be capable of giving signed informed consent
Participants are excluded from the study if any of the following criteria apply:
Medical conditions
- Any evidence (histologic, cytogenetic, molecular, hematologic, or mixed) of progressive or relapsed underlying disease after the most recent allogeneic HCT
- Post-transplant lymphoproliferative disease within 4 weeks prior to randomization
- Female participants who are pregnant or breastfeeding
- Unable to tolerate a prednisone equivalent dose of corticosteroids ≥ 1 mg/kg/day Prior/concomitant therapy
- Participant has had previous exposure to belumosudil.
- Received any previous systemic treatment for cGVHD with the following exception: Corticosteroids for cGVHD received within 7 days prior to the planned administration of IMP only if in the interest of participant.
Prior/concurrent clinical study experience
- Received any investigational agents, or any investigational device or procedure, or prohibited therapy for this study within 28 days or 5 elimination half-lives prior to randomization, whichever is longer Diagnostic assessments
- Karnofsky (if aged ≥16 years)/Lansky (if aged <16 years) Performance Score of < 60
- Platelets <25 x 109/L. Platelet transfusion is not allowed within 3 days before the screening hematological test
- Absolute neutrophil count (ANC) <0.5 x 109/L. The use of granulocyte-colony stimulating factor (G-CSF) is not allowed to reach this level during screening
- Estimated Glomerular Filtration Rate (eGFR) <30 mL/min/1.73 m2 using the MDRD-4 variable formula (if aged ≥18 years) or using the Bedside Schwartz formula (if aged <18 years)
- Aspartate aminotransferase (AST) and/or alanine aminotransferase (ALT) >3 x ULN without liver cGVHD or>5 × ULN with liver) cGVHD
- Total bilirubin >1.5 × (ULN) (>3 × ULN if Gilbert syndrome)
- Participant has forced expiratory volume in 1 second (FEV1) of predicted ≤39% or has lung score of 3 according to NIH consensus diagnostic and staging criteria (2014)
- History or other evidence of severe illness or any other conditions that would make the participant, in the opinion of the Investigator, unsuitable for the study (such as malabsorption syndromes, poorly controlled psychiatric disease or coronary artery disease)
- Known history of human immunodeficiency virus (HIV)
- Active viral disease including hepatitis B virus (HBV) or hepatitis C virus (HCV)
- Active uncontrolled cytomegalovirus (CMV) and Epstein-Barr virus (EBV) infection. Infections are considered controlled if appropriate therapy has been instituted and, at the time of screening, no signs of infection worsening are present according to Investigator's judgement
- Diagnosed or treated for another malignancy other than the underlying disease allogeneic HCT was indicated for, within 3 years prior to randomization with the exception of complete resection of basal cell carcinoma or squamous cell carcinoma of the skin, an in-situ malignancy, or low risk prostate cancer after curative therapy
- Unable to swallow tablets
- Participant not suitable for participation, whatever the reason, as judged by the Investigator, including medical or clinical conditions, or participants potentially at risk of noncompliance to study procedures
- Any active, uncontrolled infections assessed to be clinically significant by the Investigator
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description Belumosudil Belumosudil Participants will receive belumosudil 200 mg tablets per os(PO) once daily (QD) per 28-day cycles starting on Day 1 until discontinuation criteria are met or until end of study Note: 200mg two times a day (BID) is used in some cases, when the subject is taking a proton pump inhibitor or a strong CYP3A4 inducer) Belumosudil Prednisone Participants will receive belumosudil 200 mg tablets per os(PO) once daily (QD) per 28-day cycles starting on Day 1 until discontinuation criteria are met or until end of study Note: 200mg two times a day (BID) is used in some cases, when the subject is taking a proton pump inhibitor or a strong CYP3A4 inducer) Belumosudil Prednisolone Participants will receive belumosudil 200 mg tablets per os(PO) once daily (QD) per 28-day cycles starting on Day 1 until discontinuation criteria are met or until end of study Note: 200mg two times a day (BID) is used in some cases, when the subject is taking a proton pump inhibitor or a strong CYP3A4 inducer) Placebo Placebo Participants will receive matching placebo tablets PO QD per 28-day cycles starting on Day 1 until discontinuation criteria are met or until end of study Placebo Prednisone Participants will receive matching placebo tablets PO QD per 28-day cycles starting on Day 1 until discontinuation criteria are met or until end of study Placebo Prednisolone Participants will receive matching placebo tablets PO QD per 28-day cycles starting on Day 1 until discontinuation criteria are met or until end of study
- Primary Outcome Measures
Name Time Method Event-Free Survival (EFS) Until the end of the study (up to 5 years since first patient in). From the date of randomization to the date of any predefined event, whichever occurs first
- Secondary Outcome Measures
Name Time Method Modified Lee Symptom Scale (mLSS) Until the end of the study (up to 5 years since first patient in). Proportion of participants who achieve a clinically relevant reduction in mLSS of at least 6 points from baseline (Only in participants at least 18 years of age)
Durable overall response rate Until the end of the study (up to 5 years since first patient in). Proportion of participants who achieve an overall response (PR or CR) as per 2014 NIH consensus response criteria by 48 weeks and maintained the response for a duration of at least 6 months
Rate of corticosteroid withdrawal Until the end of the study (up to 5 years since first patient in). Proportion of participants who successfully discontinue all systemic corticosteroids for cGVHD for at least 30 days before the occurrence of cGVHD progression, or start of a new systemic treatment for cGVHD, relapse or recurrence of the underlying disease, or unacceptable toxicity
Overall response rate (ORR) Until the end of the study (up to 5 years since first patient in). Proportion of participants who achieve an overall response (CR or PR) as per 2014 NIH consensus response criteria at any time before the start of new systemic treatment for cGVHD
ORR by 24 weeks Until the end of the study (up to 5 years since first patient in). Proportion of participants who achieve an overall response (CR or PR) as per 2014 NIH consensus response criteria by 24 weeks (Cycle 7 Day 1) before the start of new systemic treatment for cGVHD
Duration of response (DOR) Until the end of the study (up to 5 years since first patient in). Time from the date of the first response to the date of cGVHD progression, start of new systemic treatment for cGVHD, or death, whichever occurs first. DOR is determined only for participants who achieved overall response (PR or CR) as per 2014 NIH consensus response criteria
Dose reduction in corticosteroid Until the end of the study (up to 5 years since first patient in). Proportion of participants with a reduction in daily corticosteroid dose
Failure Free Survival (FFS) Until the end of the study (up to 5 years since first patient in). Failure Free Survival (FFS) is defined as the time from the date of randomization to the date of start of a new systemic treatment for cGVHD, relapse or recurrence of the underlying disease, or death, whichever occurs first.
Change in patient reported outcome (PRO) Until the end of the study (up to 5 years since first patient in). Change from baseline in Patient-Reported Outcomes Measurement Information System Global Health (PROMIS-GH) (Only in participants at least 18 years of age) and the European Quality of Life Group Questionnaire with 5 Dimensions and 5 Levels (EQ5D5L)
Number of participants with treatment-emergent adverse events [TEAEs], serious TEAEs, and adverse events of special interest (AESIs) Until the end of the study (up to 5 years since first patient in). Overall survival Until the end of the study (up to 5 years since first patient in). The time from the date of randomization to the date of death due to any cause
Time to response (TTR) Until the end of study (up to 5 years since first patient in) Time to Response is defined as the time from randomization to the date the patient has first response (CR or PR).
Response by organ Until the end of study (up to 5 years since first patient in) Proportion of participants who achieve CR or PR as per NIH consensus response criteria (2014) at any time point in each involved organ and before the start of a new systemic therapy for cGVHD.
Trial Locations
- Locations (147)
Investigational Site Number : 1240008
🇨🇦Saskatoon, Saskatchewan, Canada
Investigational Site Number : 1560009
🇨🇳Zhengzhou, China
Hospital Niño Jesús-Site Number : 7240002
🇪🇸Madrid, Spain
Investigational Site Number : 7520003
🇸🇪Gothenburg, Sweden
Investigational Site Number : 7520001
🇸🇪Huddinge, Sweden
Investigational Site Number : 7520002
🇸🇪Lund, Sweden
Investigational Site Number : 7920006
🇹🇷Adana, Turkey
Investigational Site Number : 7920002
🇹🇷Ankara, Turkey
Investigational Site Number : 7920004
🇹🇷Ankara, Turkey
Investigational Site Number : 7920001
🇹🇷Ankara, Turkey
University of Arkansas for Medical Sciences-Site Number : 8400019
🇺🇸Little Rock, Arkansas, United States
City of Hope National Medical Center- Site Number : 8400001
🇺🇸Duarte, California, United States
University of California San Francisco - Parnassus Heights- Site Number : 8400035
🇺🇸San Francisco, California, United States
AdventHealth Orlando- Site Number : 8400023
🇺🇸Orlando, Florida, United States
Emory University School of Medicine - Atlanta- Site Number : 8400020
🇺🇸Atlanta, Georgia, United States
Northwestern University- Site Number : 8400017
🇺🇸Chicago, Illinois, United States
Indiana University Health University Hospital- Site Number : 8400006
🇺🇸Indianapolis, Indiana, United States
University of Kentucky Chandler Medical Center- Site Number : 8400024
🇺🇸Lexington, Kentucky, United States
Johns Hopkins Hospital- Site Number : 8400033
🇺🇸Baltimore, Maryland, United States
Dana Farber Cancer Institute Site Number : 8400005
🇺🇸Boston, Massachusetts, United States
Karmanos Cancer Institute - Detroit- Site Number : 8400013
🇺🇸Detroit, Michigan, United States
UNC Children's Hospital- Site Number : 8400025
🇺🇸Chapel Hill, North Carolina, United States
Atrium Health Wake Forest Baptist Medical Center - Winston-Salem - Medical Center Boulevard- Site Number : 8400007
🇺🇸Winston-Salem, North Carolina, United States
Oncology Hematology Care - Kenwood- Site Number : 8400030
🇺🇸Cincinnati, Ohio, United States
The Ohio State University Wexner Medical Center - Ohio State Outpatient Care Upper Arlington- Site Number : 8400026
🇺🇸Columbus, Ohio, United States
Oregon Health and Science University- Site Number : 8400027
🇺🇸Portland, Oregon, United States
University of Pittsburgh Medical Center - Hillman Cancer Center- Site Number : 8400008
🇺🇸Pittsburgh, Pennsylvania, United States
Sarah Cannon Research Institute Site Number : 8400003
🇺🇸Nashville, Tennessee, United States
St. David's South Austin Medical Center- Site Number : 8400002
🇺🇸Austin, Texas, United States
Texas Oncology - Dallas - Worth Street- Site Number : 8400010
🇺🇸Dallas, Texas, United States
Texas Transplant Institute - Methodist Hospital- Site Number : 8400037
🇺🇸San Antonio, Texas, United States
University of Virginia Comprehensive Cancer Center-Site Number : 8400031
🇺🇸Charlottesville, Virginia, United States
Fred Hutchinson Cancer Research Center- Site Number : 8400004
🇺🇸Seattle, Washington, United States
University of Wisconsin Carbone Cancer Center-Site Number : 8400029
🇺🇸Madison, Wisconsin, United States
Investigational Site Number : 0320006
🇦🇷Pilar, Buenos Aires, Argentina
Investigational Site Number : 0320005
🇦🇷Buenos Aires, Ciudad De Buenos Aires, Argentina
Investigational Site Number : 0320002
🇦🇷Buenos Aires, Ciudad De Buenos Aires, Argentina
Investigational Site Number : 0320003
🇦🇷Buenos Aires, Argentina
Investigational Site Number : 0320001
🇦🇷Buenos Aires, Argentina
Investigational Site Number : 0320004
🇦🇷Córdoba, Argentina
Investigational Site Number : 0360005
🇦🇺Westmead, New South Wales, Australia
Investigational Site Number : 0360003
🇦🇺Brisbane, Queensland, Australia
Investigational Site Number : 0360001
🇦🇺Melbourne, Victoria, Australia
Investigational Site Number : 0360004
🇦🇺Murdoch, Western Australia, Australia
Investigational Site Number : 0400003
🇦🇹Graz, Austria
Investigational Site Number : 0400001
🇦🇹Linz, Austria
Cliniques Universitaires St. Luc-Investigational Site Number : 0560005
🇧🇪Woluwe, Brussels, Belgium
UZ Leuven-Investigational Site Number : 0560001
🇧🇪Leuven, Vlaams-Brabant, Belgium
Investigational Site Number : 0560006
🇧🇪Bruges, Belgium
UZ Gent-Investigational Site Number : 0560003
🇧🇪Gent, Belgium
CHU de Liège-Investigational Site Number : 0560004
🇧🇪Liège, Belgium
AZ Delta-Investigational Site Number : 0560002
🇧🇪Roeselare, Belgium
Hospital de Clinicas da Universidade Federal do Parana- Site Number : 0760008
🇧🇷Curitiba, Paraná, Brazil
Hospital de Base de São José do Rio Preto- Site Number : 0760006
🇧🇷São José Do Rio Preto, São Paulo, Brazil
INCA - Hospital do Câncer - Rio de Janeiro - Praça Da Cruz Vermelha- Site Number : 0760007
🇧🇷Rio de Janeiro, Brazil
Hospital das Clinicas da Faculdade de Medicina da Universidade de Sao Paulo- Site Number : 0760004
🇧🇷São Paulo, Brazil
Hospital Israelita Albert Einstein- Site Number : 0760003
🇧🇷São Paulo, Brazil
Investigational Site Number : 1240007
🇨🇦Calgary, Alberta, Canada
Investigational Site Number : 1240005
🇨🇦Toronto, Ontario, Canada
Hôpital Maisonneuve Rosemont-Investigational Site Number : 1240001
🇨🇦Montreal, Quebec, Canada
CHU Sainte-Justine-Site Number : 1240003
🇨🇦Montreal, Quebec, Canada
Investigational Site Number : 1240002
🇨🇦Montreal, Quebec, Canada
Investigational Site Number : 1560019
🇨🇳Beijing, China
Investigational Site Number : 1560012
🇨🇳Changchun, China
Investigational Site Number : 1560010
🇨🇳Changsha, China
Investigational Site Number : 1560002
🇨🇳Hangzhou, China
Investigational Site Number : 1560011
🇨🇳Fuzhou, China
Investigational Site Number : 1560005
🇨🇳Guangzhou, China
Investigational Site Number : 1560014
🇨🇳Hefei, China
Investigational Site Number : 1560001
🇨🇳Suzhou, China
Investigational Site Number : 1560008
🇨🇳Jinan, China
Investigational Site Number : 1560007
🇨🇳Jinan, China
Investigational Site Number : 1560006
🇨🇳Suzhou, China
Investigational Site Number : 1560003
🇨🇳Tianjin, China
Investigational Site Number : 1560004
🇨🇳Tianjin, China
Investigational Site Number : 1560013
🇨🇳Wuhan, China
Investigational Site Number : 1560015
🇨🇳Wuhan, China
Interni hematologicka a onkologicka klinika Fakultni nemocnice Brno-Site Number : 2030003
🇨🇿Brno, Czechia
IV. Interni hematologicka klinika, Fakultni nemocnice Hradec Kralove-Site Number : 2030002
🇨🇿Hradec Kralove, Czechia
Klinika hematoonkologie, Fakultni nemocnice Ostrava-Site Number : 2030001
🇨🇿Ostrava, Czechia
Ustav hematologie a krevni transfuze-Site Number : 2030004
🇨🇿Praha, Czechia
Rigshospitalet Copenhagen University Hospital-Investigational Site Number : 2080002
🇩🇰Copenhagen, Capital, Denmark
Odense University Hospital-Investigational Site Number : 2080003
🇩🇰Odense, Funen, Denmark
Department of hematology-Investigational Site Number : 2080001
🇩🇰Aarhus, Jutland, Denmark
Institut Paoli Calmettes-Investigational Site Number : 2500004
🇫🇷Marseille, France
CHU Hotel Dieu-Investigational Site Number : 2500005
🇫🇷Nantes, France
Investigational Site Number : 2500003
🇫🇷Paris, France
Investigational Site Number : 2500001
🇫🇷Paris, France
CHU Bordeaux-Hôpital Haut-Lévêque-Investigational Site Number : 2500002
🇫🇷Pessac, France
Hôpital Lyon Sud-Investigational Site Number : 2500007
🇫🇷Pierre Benite, France
Hôpital Pontchaillou - CHU de Rennes-Investigational Site Number : 2500008
🇫🇷Rennes, France
Investigational Site Number : 2500006
🇫🇷Vandœuvre-lès-nancy, France
Investigational Site Number : 2760007
🇩🇪Berlin, Germany
Investigational Site Number : 2760003
🇩🇪Cologne, Germany
Investigational Site Number : 2760001
🇩🇪Dresden, Germany
Investigational Site Number : 2760005
🇩🇪Freiburg, Germany
Investigational Site Number : 2760002
🇩🇪Hamburg, Germany
Investigational Site Number : 2760010
🇩🇪Kiel, Germany
Investigational Site Number : 2760009
🇩🇪Münster, Germany
Investigational Site Number : 2760006
🇩🇪Regensburg, Germany
Investigational Site Number : 2760008
🇩🇪Tübingen, Germany
Nosokomeio Paidon I Agia Sofia-Site Number : 3000002
🇬🇷Athens, Greece
General Hospital of Thessaloniki "George Papanikolaou"-Site Number : 3000001
🇬🇷Thessaloniki, Greece
Investigational Site Number : 3440001
🇭🇰Pok Fu Lam, Hong Kong
Investigational Site Number : 3760002
🇮🇱Haifa, Israel
Investigational Site Number : 3760005
🇮🇱Jerusalem, Israel
Investigational Site Number : 3760006
🇮🇱Petah Tikva, Israel
Investigational Site Number : 3760003
🇮🇱Ramat Gan, Israel
Investigational Site Number : 3760004
🇮🇱Ramat Gan, Israel
Investigational Site Number : 3760001
🇮🇱Tel Aviv, Israel
Investigational Site Number : 3800005
🇮🇹Genoa, Genova, Italy
Investigational Site Number : 3800002
🇮🇹Rozzano, Lombardia, Italy
Investigational Site Number : 3800009
🇮🇹Milan, Milano, Italy
Investigational Site Number : 3800001
🇮🇹Rome, Roma, Italy
Investigational Site Number : 3800007
🇮🇹Turin, Torino, Italy
Investigational Site Number : 3800003
🇮🇹Bergamo, Italy
Investigational Site Number : 3800004
🇮🇹Bologna, Italy
Investigational Site Number : 3800011
🇮🇹Pavia, Italy
Investigational Site Number : 3800010
🇮🇹Perugia, Italy
Investigational Site Number : 3800006
🇮🇹Reggio Calabria, Italy
Investigational Site Number : 3800012
🇮🇹Torette, Italy
Investigational Site Number : 3800008
🇮🇹Udine, Italy
Investigational Site Number : 4100003
🇰🇷Seoul, Seoul-teukbyeolsi, Korea, Republic of
Investigational Site Number : 4100001
🇰🇷Seoul, Seoul-teukbyeolsi, Korea, Republic of
Amsterdam Universitair Medisch Centrum-Site Number : 5280005
🇳🇱Amsterdam, Netherlands
Investigational Site Number : 5280003
🇳🇱Groningen, Netherlands
Investigational Site Number : 5280002
🇳🇱Rotterdam, Netherlands
Investigational Site Number : 5280001
🇳🇱Utrecht, Netherlands
Investigational Site Number : 6160001
🇵🇱Gdansk, Pomorskie, Poland
Investigational Site Number : 6200003
🇵🇹Lisbon, Portugal
Investigational Site Number : 6200002
🇵🇹Lisbon, Portugal
Hospital Regional Universitarioa de Malaga-Site Number : 7240003
🇪🇸Málaga, Andalucia, Spain
Hospital Universitario Virgen del Rocío.-Site Number : 7240008
🇪🇸Sevilla, Andalucia, Spain
Investigational Site Number : 7240005
🇪🇸Barcelona, Barcelona [Barcelona], Spain
Investigational Site Number : 7240011
🇪🇸Santander, Cantabria, Spain
Hospital Universitario de Salamanca-Site Number : 7240007
🇪🇸Salamanca, Castilla Y Leon, Spain
ICO Institut Català d'Oncologia-Site Number : 7240006
🇪🇸Barcelona, Cataluña, Spain
Hospital Universitari i Politècnic La Fe-Site Number : 7240001
🇪🇸Valencia, Comunidad Valenciana, Spain
Investigational Site Number : 7240004
🇪🇸Madrid, Madrid, Comunidad De, Spain
Investigational Site Number : 7240012
🇪🇸Valencia, Valenciana, Comunidad, Spain
Investigational Site Number : 8260006
🇬🇧Cardiff, Vale Of Glamorgan, The, United Kingdom
Investigational Site Number : 7920005
🇹🇷Istanbul, Turkey
Investigational Site Number : 7920003
🇹🇷Izmir, Turkey
Investigational Site Number : 8260003
🇬🇧Leeds, United Kingdom
Investigational Site Number : 8260002
🇬🇧London, United Kingdom
Investigational Site Number : 8260001
🇬🇧Manchester, United Kingdom
Investigational Site Number : 8260004
🇬🇧Newcastle Upon Tyne, United Kingdom